Loading...
Spiro azepane-oxazolidinones as Kv1.3 potassium channel blockers - WO2010066840
This article evaluates a patent application from Solvay Pharmaceuticals, which claims spiro azepane-oxazolidinones as novel blockers of the voltage-gated potassium channel Kv1.3 for the treatment of diabetes, psoriasis, obesity, transplant rejection and T-cell mediated autoimmune diseases such as rh...
Saved in:
| Main Author: | |
|---|---|
| Format: | Artigo |
| Language: | Inglês |
| Published: |
2010
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2988097/ https://ncbi.nlm.nih.gov/pubmed/20954790 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1517/13543776.2010.528392 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|